Checkpoint Blockade Finally Breaks Through in Ovarian Cancer

(MedPage Today) — BERLIN — After multiple failed attempts, an immune checkpoint inhibitor has broken through and landed a significant overall survival (OS) benefit in ovarian cancer, phase III study results showed.
KEYNOTE-B96 enrolled patients…